Skip to main content
CSL
  • Global Selector
  • Newsroom
  • Partnering
  • Contact
  • We Are CSL
    We Are CSL
    Our Businesses and Products
    Vita: Original Stories
    Our Leadership
    Worldwide Locations
    Corporate Governance
    Our Businesses and Products
    CSL Behring
    CSL Seqirus
    CSL Vifor
    Corporate Governance
    Code of Responsible Business Practice
    Core Policies

    Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.

    Read the Stories

    CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.

    Our Businesses and Products
  • Patients & Public Health
    Patients & Public Health
    Rare & Serious Diseases
    Iron Deficiency
    Nephrology
    Vaccines
    Patient Support & Organizations
    Rare & Serious Diseases
    Immunodeficiency and Autoimmune Diseases
    Hereditary Bleeding Disorders
    Hereditary Angioedema
    Alpha 1 Antitrypsin Deficiency
    Iron Deficiency
    Iron Deficiency Patient Stories
    Nephrology
    Nephrology Patient Stories
    Vaccines
    COVID-19
    Pandemic Response
    In-Licensing
    Antivenoms and Q fever Vaccine
    Patient Support & Organizations
    CSL Behring USA Support & Assistance Programs
    CSL Vifor Managed Access Programs
    LEAD Grants
    CSL Community Impact Awards

    Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.

    CSL Behring: Rare & Serious Diseases

    Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.

    CSL Seqirus: Vaccines
  • R&D
    R&D
    R&D Capabilities
    Awards, Grants and Initiatives
    World-Class R&D Network
    Product Pipeline
    Clinical Studies at CSL
    Clinical Studies at CSL
    Current Clinical Trials
    Research Practices
    How to Participate
    Clinical Studies FAQs

    R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.

    R&D Capabilities

    One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.

    Awards, Grants and Initiatives
  • Sustainability
    Sustainability
    Healthier Environment
    Healthier Communities
    Promising Futures
    Governance
    Data and Reporting Centre
    Healthier Environment
    Climate Resilience
    Energy
    Water, Waste & Biodiversity
    Healthier Communities
    Product Safety & Quality
    Innovation and R&D
    Access and Affordability
    Responsible & Resilient Supply Chain
    Donor Experience
    Patient Experience
    Promising Futures
    Talent and Culture
    Health, Safety & Wellbeing
    Inclusion and Belonging
    Governance
    Ethics & Transparency
    Data Protection & Privacy
    Stakeholder Engagement & Material Topics
    Data and Reporting Centre
    Annual Publications
    Policies
    Key Performance Data Summary

    As part of our broader sustainability strategy to build a more sustainable future, CSL commits to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY2030.

    Learn About Our Targets

    Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.

    Supporting Our Communities
  • Careers
    Careers
    Inclusion and Belonging
    How CSL Supports Your Well-being
    Early Careers at CSL
    Early Careers at CSL
    Apprenticeships
    Internships at CSL
    Graduate Rotational Programs at CSL

    At CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out.

    Read About Our Approach to Inclusion and Belonging

    Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!

    Early Careers at CSL
  • Investors
CSL

  • We Are CSL
    • We Are CSL
    • Our Businesses and Products
      • Our Businesses and Products
      • CSL Behring
      • CSL Seqirus
      • CSL Vifor
    • Vita: Original Stories
    • Our Leadership
    • Worldwide Locations
    • Corporate Governance
      • Corporate Governance
      • Code of Responsible Business Practice
      • Core Policies
  • Patients & Public Health
    • Patients & Public Health
    • Rare & Serious Diseases
      • Rare & Serious Diseases
      • Immunodeficiency and Autoimmune Diseases
      • Hereditary Bleeding Disorders
      • Hereditary Angioedema
      • Alpha 1 Antitrypsin Deficiency
    • Iron Deficiency
      • Iron Deficiency
      • Iron Deficiency Patient Stories
    • Nephrology
      • Nephrology
      • Nephrology Patient Stories
    • Vaccines
      • Vaccines
      • COVID-19
      • Pandemic Response
      • In-Licensing
      • Antivenoms and Q fever Vaccine
    • Patient Support & Organizations
      • Patient Support & Organizations
      • CSL Behring USA Support & Assistance Programs
      • CSL Vifor Managed Access Programs
      • LEAD Grants
      • CSL Community Impact Awards
  • R&D
    • R&D
    • R&D Capabilities
    • Awards, Grants and Initiatives
    • World-Class R&D Network
    • Product Pipeline
    • Clinical Studies at CSL
      • Clinical Studies at CSL
      • Current Clinical Trials
      • Research Practices
      • How to Participate
      • Clinical Studies FAQs
  • Sustainability
    • Sustainability
    • Healthier Environment
      • Healthier Environment
      • Climate Resilience
      • Energy
      • Water, Waste & Biodiversity
    • Healthier Communities
      • Healthier Communities
      • Product Safety & Quality
      • Innovation and R&D
      • Access and Affordability
      • Responsible & Resilient Supply Chain
      • Donor Experience
      • Patient Experience
    • Promising Futures
      • Promising Futures
      • Talent and Culture
      • Health, Safety & Wellbeing
      • Inclusion and Belonging
    • Governance
      • Governance
      • Ethics & Transparency
      • Data Protection & Privacy
      • Stakeholder Engagement & Material Topics
    • Data and Reporting Centre
      • Data and Reporting Centre
      • Annual Publications
      • Policies
      • Key Performance Data Summary
  • Careers
    • Careers
    • Inclusion and Belonging
    • How CSL Supports Your Well-being
    • Early Careers at CSL
      • Early Careers at CSL
      • Apprenticeships
      • Internships at CSL
      • Graduate Rotational Programs at CSL
  • Investors
  • Newsroom
  • Partnering
  • Contact
  • Global Selector

CSL's 2025 Community Impact Award Winners

Meet our 2025 winners – organizations that are making a positive difference for patients and communities across Australia

Read the Article

Would you like to read our 2025 Annual Report? Click here to view or download the Annual Report →   |    CSL's 2025 Full Year Financial Results Click here for Full Information including Webcast Recording →

CSL
CSL Behring
CSL Seqirus
CSL Vifor

CSL. Always Evolving for a Better World.

CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.

Our Businesses and Products

CSL Behring. Leading the Way in Treating Rare and Serious Diseases.

CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.

More About CSL Behring

CSL Seqirus. Global Vaccine Leader.

Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.

More About CSL Seqirus

CSL Vifor. Changing the Game in Iron Deficiency and Nephrology.

The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.

More About CSL Vifor
CSL Logo The text 'CSL' in bold white all capitals.
CSL Behring Logo The text 'CSL Behring' in bold white.
CSL Seqirus Logo The text 'CSL Seqirus' in bold white.
CSL Vifor Logo The text 'CSL Vifor' in bold white.
CSL Logo

CSL. Always Evolving for a Better World.

CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.

Our Businesses and Products
CSL Behring Logo

CSL Behring. Leading the Way in Treating Rare and Serious Diseases.

CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.

More About CSL Behring
CSL Seqirus Logo

CSL Seqirus. Global Vaccine Leader.

Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.

More About CSL Seqirus
CSL Vifor Logo

CSL Vifor. Changing the Game in Iron Deficiency and Nephrology.

The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.

More About CSL Vifor

Vita: Original Stories

'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.

Pregnant woman getting a blood test. Women are at risk of anemia.

Closing the Gender Gap in Anemia Care

Anemia disrupts the lives of women around the world. The Global Alliance for Patient Access urges global policymakers to adop…

07 Oct 2025
A first-of-its kind program created by Wake Tech Community College aims to meet the biopharmaceutical sector’s need for skilled employees. In photo, CSL Seqirus’ Mark Lockette, Cody Mercer, Connor Bowersox, and Deborah Hittel. Photo credit: NCBiotech

Skilling Up in BioMechatronics

A first-of-its kind program created by Wake Tech Community College aims to meet the biopharmaceutical sector’s need for skill…

01 Oct 2025
Six CSL colleagues share the personal impact of women's health issues.

Videos: Making Women's Health a Priority

Hear six personal stories from CSL colleagues in Australia about how women’s health care has impacted their lives. Together, …

18 Sep 2025
CSL scientist in Switzerland

Careers at CSL

We are committed to helping employees fulfill their career aspirations while working in a values-based culture. Are you next?

Pictured: A CSL employee in Bern, Switzerland

Promising Futures at CSL

CSL on LinkedIn

Follow us!
LinkedIn
7 Oct

We’re excited to welcome our newest apprentices and dual students to the CSL Behring site in Marburg, Germany! They’re ready to dive into projects, connect with their teams, and start developing the skills that will shape their careers. At CSL, we’re proud to support the next generation of talent and can’t wait to see the impact they’ll make—both here at CSL and on the future of healthcare. #CSLCareers #PromisingFutures #EarlyCareers #TeamCSL #CSL

LinkedInPostImage
LinkedIn
6 Oct

CSL Seqirus apprentices like Connor Bowersox and Cody Mercer are paving the way in Wake Technical Community College ’s trailblazing 8-month BioMechatronics Apprenticeship Program in Raleigh, North Carolina! This unique partnership is building a nimble talent pipeline for the region’s biopharma sector, combining hands-on learning and classroom excellence. We're proud that previous apprentices are now valued members of the Holly Springs team at CSL Seqirus. Interested in joining the next generation of innovators? Learn more: https://bit.ly/3IZvmq3 #CSL #CSLSeqirus #ApprenticeshipProgram #NorthCarolina #MaintenanceTechnician #HollySprings

LinkedIn
2 Oct

Breakthroughs don’t happen in isolation. They happen when bright minds come together with one purpose: advancing science for patients. At CSL, collaboration fuels our discoveries and accelerates our impact — across teams, across disciplines and across the globe. Together, we make innovation possible. Learn more about who we are: https://bit.ly/4nvNQ0f #CSL #Values #InnovationForLife

LinkedIn
1 Oct

October is #PlasmaAwarenessMonth , an opportunity to thank our plasma donors for their generosity and to bring awareness of the important role that plasma plays in helping patients. Our plasma-derived therapies are made possible by the donation of plasma, and these therapies are used to help treat certain serious and rare conditions, including immune deficiencies and bleeding disorders. In certain medical situations, plasma-derived products may also be used in trauma care and maternal health. We encourage everyone to learn more about the #PowerofPlasma , to share the message, and consider becoming a donor themselves. Learn more here: https://bit.ly/4n3pFFL #CSLPlasma #PlasmaAwarenessMonth #DonatePlasma

LinkedInPostImage
LinkedIn
29 Sep

World Heart Day is a reminder to make every heartbeat count and to ensure that no one misses a beat when it comes to heart health. At CSL, we’re committed to supporting access to care and reducing inequities for people worldwide. #CSL #WorldHeartDay #DontMissABeat https://bit.ly/4gRCS2Y

LinkedInPostImage
LinkedIn
26 Sep

At CSL, we are committed to supporting patients with severe and rare diseases such as IgA Nephropathy, a leading cause of kidney failure. We welcome the publication of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy \(IgAN\) and Immunoglobulin A Vasculitis \(IgAV\). The guideline brings valuable new recommendations and important updates designed to improve and harmonize standards of diagnosis and treatment — and ultimately optimize patient care. We are confident that this milestone will enable us to further expand our role in supporting patients with IgA Nephropathy. Read the published guideline here: https://lnkd.in/dRMkFDf2 Learn more: https://lnkd.in/ejj87aqN #CSL #IgANephropathy #RareKidneyDisease #PatientCare #ClinicalGuidelines #KDIGO2024 #KidneyHealth  

LinkedIn
25 Sep

This week we welcomed author and Cultural Intelligence \(CQ\) expert Anthony López for a powerful session on the role of CQ in today’s workplace. Anthony shared how CQ can foster empathy, strengthen leadership and create an environment where everyone feels they truly belong. Grateful for the opportunity to learn from such an inspiring voice. #CSL #HispanicHeritageMonth

LinkedInPostImage
LinkedIn
25 Sep

At CSL, quality is at the heart of everything we do – driving safe, effective therapies that make a real difference for patients. #CSL #QualityInCare #InnovationForLife https://bit.ly/46Av94n

LinkedInPostImage
LinkedIn
24 Sep

Let’s go Dee! #CSL employees will be cycling alongside Dee, an Alpha-1 Antitrypsin Deficiency patient, in this weekend’s Escape to the Cape Bike Trek. Leave some words of encouragement for Dee, who is hoping to beat her personal best in three days of cycling on Cape Cod! #Alpha1 #EscapetotheCape #CommunityImpact

LinkedIn
23 Sep

Watch all six personal stories from #CSL colleagues talking about the critical importance of #womenshealth . We shared them recently for Australia’s Women’s Health Week. On the other side of the world, philanthropist Melinda French Gates just announced a partnership that will invest $100 million in #womenshealthresearch . https://bit.ly/4nK3CED

We Are CSL

  • Our Businesses and Products
  • Vita: Original Stories
  • Our Leadership
  • Worldwide Locations
  • Corporate Governance

Patients & Public Health

  • Rare & Serious Diseases
  • Iron Deficiency
  • Nephrology
  • Vaccines
  • Patient Support & Organizations

R&D

  • R&D Capabilities
  • Awards, Grants and Initiatives
  • World-Class R&D Network
  • Product Pipeline
  • Clinical Studies at CSL

Sustainability

  • Healthier Environment
  • Healthier Communities
  • Promising Futures
  • Governance
  • Data and Reporting Centre

Careers

  • Inclusion and Belonging
  • How CSL Supports Your Well-being
  • Early Careers at CSL

Investors

Terms of Use Cookie Policy Global Privacy Policy Accessibility Statement Sitemap
  • Terms of Use
  • Cookie Policy
  • Global Privacy Policy
  • Accessibility Statement
  • Sitemap
CSL logo

CSL, All Rights Reserved © 2025

  • Instagram

CSL
  • CSL (CSL Behring's Parent Company)
CSL Behring Worldwide

Americas

  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Mexico

Asia Pacific

  • Australia
  • China
  • Japan
  • Korea
  • Singapore
  • Taiwan

Middle East

  • Saudi Arabia
  • United Arab Emirates (MEA)

Europe

  • Austria
  • Belgium and Luxembourg
  • Czech Republic
  • Denmark
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Italy
  • Netherlands
  • Norway
  • Poland
  • Slovakia
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Kingdom
CSL Plasma (CSL Behring Subsidiary)
  • CSL Plasma US
  • CSL Plasma Germany
  • CSL Plasma Hungary